Wilmington, Delaware-based Earendil Labs has entered a research collaboration with Genentech to discover and develop multiple bispecific antibody programs in oncology, with Earendil receiving a USD 55 million upfront payment and development, regulatory, and sales milestones that bring total potential deal value in excess of USD 1.5 billion.
Under the agreement, Earendil leads antibody discovery and research through early clinical development for programs directed at pre-agreed target combinations, after which Genentech assumes responsibility for global clinical development and commercialization. Specific milestone values, royalty tiers, and program count were not disclosed.
Earendil describes its platform as integrating machine learning, generative protein engineering, and high-throughput experimental techniques to optimize functionality, manufacturability, and developability of protein-based biologics. The company operates alongside an affiliate, Helixon Therapeutics.